Merck & Co., Inc. (NYSE:MRK) Given New $161.00 Price Target at Leerink Partners

Key Points

• Leerink Partners raised Merck’s price target to $161 from $127 and maintained an “outperform” rating, implying about 9% upside. Other analysts have also increased targets, with the stock carrying a consensus “Moderate Buy” rating and average target of $150.33.
• Merck shares recently traded at $147.64, near their 52-week high, while quarterly results exceeded expectations: revenue reached $16.61 billion and EPS beat consensus estimates. The company also reported 5.1% year-over-year revenue growth.
• Key risks include the expected 2028 Keytruda patent expiration and weaker GARDASIL sales. Meanwhile, insiders sold nearly $30 million of stock over the past 90 days, while institutional investors own 76.07% of the shares.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target hoisted by equities researchers at Leerink Partners from $127.00 to $161.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Leerink Partners' target price points to a potential upside of 9.05% from the company's current price.

A number of other research analysts have also recently commented on the company. Bank of America boosted their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Argus lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a research report on Tuesday, August 25th. BMO Capital Markets boosted their target price on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, August 20th. Finally, Guggenheim upped their target price on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a "buy" rating in a research report on Tuesday. Sixteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $150.33.

Merck & Co., Inc. Stock Down 0.6%

Shares of NYSE:MRK traded down $0.82 during trading on Wednesday, reaching $147.64. 2,096,228 shares of the stock traded hands, compared to its average volume of 10,735,682. The stock has a market cap of $364.26 billion, a P/E ratio of 118.09, a price-to-earnings-growth ratio of 6.54 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a 50-day moving average of $135.46 and a two-hundred day moving average of $123.92. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Insider Activity at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares of the company's stock, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Williams sold 52,847 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. 0.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the fourth quarter valued at $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Graney & King LLC grew its position in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after acquiring an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Guggenheim raised its price target on Merck to $170 from $146 and maintained a “Buy” rating, implying approximately 15% upside from recent levels. The upgrade reinforces confidence in Merck’s earnings outlook and pipeline prospects. Benzinga analyst rating report
• Positive Sentiment: Merck’s stock has gained about 85% over the past year and is trading close to its 52-week high. Coverage points to continued Keytruda-driven growth, as well as newer products and pipeline programs that could help offset the expected impact of Keytruda’s patent expiration later this decade. Merck trading near 52-week high
• Neutral Sentiment: Merck will participate in Morgan Stanley’s 24th Annual Global Healthcare Conference. The event could provide updates on Keytruda, GARDASIL, the pipeline and long-term strategy, but no new operating guidance was included in the announcement. Merck Morgan Stanley healthcare conference
• Neutral Sentiment: Merck outperformed its industry peers in the latest session despite broader losses, indicating relative investor support; however, the report did not identify a new company-specific catalyst. Merck outperforms competitors
• Negative Sentiment: Investors are shifting attention away from the earlier GARDASIL sales decline toward Merck’s longer-term growth story. Nevertheless, the product setback and the 2028 patent cliff remain important risks to future revenue and valuation, particularly with MRK trading at an elevated earnings multiple. Merck GARDASIL outlook

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.